Section
Pipeline
Late-stage drugs with significant commercial implications
PipelineEndpoints News ↗
Plus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial…
PipelineBriefing
By succeeding in the ACACIA-HCM trial, Myqorzo could become the first approved treatment for non‑obstructive h…
PipelinePharmaVoice ↗
Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrow…
PipelineFiercePharma ↗
The early FDA approval doesn't change Pfizer and Arvinas' plan to leave commercialization of the drug to a yet…
PipelineFierceBiotech ↗
Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliv…
PipelineBriefing
Auvelity, already cleared for depression, becomes the first non-antipsychotic treatment for agitation in Alzhe…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.